KindlyMD (NASDAQ:NAKA - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.
Separately, Maxim Group initiated coverage on KindlyMD in a research note on Wednesday, September 3rd. They set a "buy" rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $8.00.
Get Our Latest Stock Report on KindlyMD
KindlyMD Price Performance
Shares of NAKA stock opened at $0.96 on Wednesday. KindlyMD has a 52-week low of $0.65 and a 52-week high of $34.77. The company has a market cap of $397.10 million, a price-to-earnings ratio of -1.12 and a beta of 31.10. The business's 50 day simple moving average is $5.53.
KindlyMD (NASDAQ:NAKA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 131.09% and a negative net margin of 244.00%.The business had revenue of $0.41 million for the quarter.
About KindlyMD
(
Get Free Report)
Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider KindlyMD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KindlyMD wasn't on the list.
While KindlyMD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
